Market Overview:
The global isocitrate dehydrogenase inhibitors market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of medullary malignant tumors, rising demand for targeted therapies, and growing investments in R&D. Based on type, the global isocitrate dehydrogenase inhibitors market can be segmented into IDH1 mutant medullary malignant tumor, IDH2 mutant medullary malignant tumor, and others. The IDH1 mutant medullary malignant tumor segment is expected to account for the largest share of the global isocitrate dehydrogenase inhibitors market in 2018. This segment is anticipated to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Based on application, the global isocitrate dehydrogenase inhibitors market can be divided into DH inhibitor, FLT3 inhibitor, hedgehog pathway inhibitor (HHI), and others.
Product Definition:
Isocitrate dehydrogenase inhibitors (IDHIs) are a class of small molecule drugs that inhibit the enzyme isocitrate dehydrogenase. IDHIs have been shown to be effective in the treatment of various types of cancer, including glioma, leukemia, and myelodysplastic syndromes.
IDH1 Mutant Medullary Malignant Tumor:
IDH1 is a gene that codes for Isocitrate Dehydrogenase, an enzyme involved in the citric acid cycle. This mutation leads to an abnormal IDH1 protein being produced which interferes with the normal function of this enzyme and causes medullary malignant tumor (MNT).
The MNT has two forms: small-cell lung cancer and non-small cell lung cancer.
IDH2 Mutant Medullary Malignant Tumor:
IDH2 is a gene that codes for Isocitrate Dehydrogenase. This enzyme converts isocitrate to 2-methylisocitrate, which in turn catalyzes the conversion of alpha-ketoglutarate to succinyl CoA. IDH2 mutation leads to an abnormal buildup of methylmalonic acid (MMA) and causes medullary malignant tumor (MCT).
Application Insights:
The other application segment includes the use of isocitrate dehydrogenase inhibitor for the treatment of drug-resistant epilepsy, neurodegenerative disorders and cardiovascular diseases. The others segment held the largest market share in 2017 due to a large number of clinical trials that have been conducted using this compound for various applications.
The most significant factors contributing to its growth are favorable regulatory outlook and increasing R&D investments by major players such as Pfizer, Merck & Co., Inc., Novartis AG and sanofi Aventis; these companies are engaged in discovering novel applications for IDH1 Inhibitors across different disease states. These inhibitors also hold potential as a new therapeutic tool against cancer which can be used either alone or in combination with chemotherapy drugs. This factor along with growing oncology awareness among patients worldwide will boost product demand over the forecast period (2017-2030).
Regional Analysis:
North America dominated the global isocitrate dehydrogenase inhibitors market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc., Eisai Co., Ltd, and Merck & Co., in this region. The U.S.-based companies are engaged in extensive R&D activities for the development of novel drugs that target cancer cells with high efficiency and low toxicity levels. These factors have resulted in a significant share captured by North America within this space over the past few years (Table 1).
However, Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising healthcare expenditure levels by various governments across emerging economies such as China and India along with increasing investment from private firms seeking potential opportunities offered by these markets (Table 2). Moreover, growing awareness about early diagnosis among patients coupled with government initiatives aimed at reducing treatment costs associated with later stages of disease are anticipated to further fuel regional growth during the forecast period Table 3).
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for Isocitrate Dehydrogenase Inhibitors in the coming years.
- Growing awareness about cancer treatments: There is a growing awareness among people about various types of cancers and their treatments. This is likely to boost the demand for Isocitrate Dehydrogenase Inhibitors in the near future.
- Rising healthcare expenditure: The global healthcare expenditure is rising rapidly, owing to which more people are able to afford expensive cancer treatments such as those involving Isocitrate Dehydrogenase Inhibitors drugs.
- Technological advancements: The pharmaceutical industry is witnessing rapid advancements in technology, which has led to the development of novel and more effective drugs such as Isocitrate Dehydrogenase Inhibitors for treating various types of cancers.. This is likely to fuel the growth of this market in the coming years.. 5) Emerging markets: A large number if emerging markets are expected witness high growth rates in th eIsocitrate Dehydrogenase inhibitors market due t othe increasing prevalence ifcancer and rising healthcare spending
Scope Of The Report
Report Attributes
Report Details
Report Title
Isocitrate Dehydrogenase Inhibitors Market Research Report
By Type
IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Others
By Application
DH Inhibitor, FLT3 Inhibitor, Hedgehog Pathway Inhibitor, Others
By Companies
AGIOS, Aslan Pharmaceuticals, Bayer, Beigene, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Philogen S.p.A., Tesaro, Tragara/Adastra, Tocagen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Isocitrate Dehydrogenase Inhibitors Market Report Segments:
The global Isocitrate Dehydrogenase Inhibitors market is segmented on the basis of:
Types
IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
DH Inhibitor, FLT3 Inhibitor, Hedgehog Pathway Inhibitor, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AGIOS
- Aslan Pharmaceuticals
- Bayer
- Beigene
- Bristol-Myers Squibb
- Celgene
- Daiichi Sankyo
- Philogen S.p.A.
- Tesaro
- Tragara/Adastra
- Tocagen
Highlights of The Isocitrate Dehydrogenase Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IDH1 Mutant Medullary Malignant Tumor
- IDH2 Mutant Medullary Malignant Tumor
- Others
- By Application:
- DH Inhibitor
- FLT3 Inhibitor
- Hedgehog Pathway Inhibitor
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Isocitrate Dehydrogenase Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Isocitrate dehydrogenase inhibitors (IDH) are medications that block the enzyme isocitrate dehydrogenase, which is responsible for breaking down isocitrate into two molecules of glucose. This can lead to an increase in blood sugar levels, and IDH inhibitors are used to treat type 2 diabetes.
Some of the major companies in the isocitrate dehydrogenase inhibitors market are AGIOS, Aslan Pharmaceuticals, Bayer, Beigene, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Philogen S.p.A., Tesaro, Tragara/Adastra, Tocagen.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Isocitrate Dehydrogenase Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Isocitrate Dehydrogenase Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Isocitrate Dehydrogenase Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Isocitrate Dehydrogenase Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Isocitrate Dehydrogenase Inhibitors Market Size & Forecast, 2018-2028
4.5.1 Isocitrate Dehydrogenase Inhibitors Market Size and Y-o-Y Growth
4.5.2 Isocitrate Dehydrogenase Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Isocitrate Dehydrogenase Inhibitors Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Type
5.2.1 IDH1 Mutant Medullary Malignant Tumor
5.2.2 IDH2 Mutant Medullary Malignant Tumor
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Isocitrate Dehydrogenase Inhibitors Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Applications
6.2.1 DH Inhibitor
6.2.2 FLT3 Inhibitor
6.2.3 Hedgehog Pathway Inhibitor
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Isocitrate Dehydrogenase Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Isocitrate Dehydrogenase Inhibitors Analysis and Forecast
9.1 Introduction
9.2 North America Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Type
9.6.1 IDH1 Mutant Medullary Malignant Tumor
9.6.2 IDH2 Mutant Medullary Malignant Tumor
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Applications
9.10.1 DH Inhibitor
9.10.2 FLT3 Inhibitor
9.10.3 Hedgehog Pathway Inhibitor
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Isocitrate Dehydrogenase Inhibitors Analysis and Forecast
10.1 Introduction
10.2 Europe Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Type
10.6.1 IDH1 Mutant Medullary Malignant Tumor
10.6.2 IDH2 Mutant Medullary Malignant Tumor
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Applications
10.10.1 DH Inhibitor
10.10.2 FLT3 Inhibitor
10.10.3 Hedgehog Pathway Inhibitor
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Isocitrate Dehydrogenase Inhibitors Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Type
11.6.1 IDH1 Mutant Medullary Malignant Tumor
11.6.2 IDH2 Mutant Medullary Malignant Tumor
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Applications
11.10.1 DH Inhibitor
11.10.2 FLT3 Inhibitor
11.10.3 Hedgehog Pathway Inhibitor
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Isocitrate Dehydrogenase Inhibitors Analysis and Forecast
12.1 Introduction
12.2 Latin America Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Type
12.6.1 IDH1 Mutant Medullary Malignant Tumor
12.6.2 IDH2 Mutant Medullary Malignant Tumor
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Applications
12.10.1 DH Inhibitor
12.10.2 FLT3 Inhibitor
12.10.3 Hedgehog Pathway Inhibitor
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Isocitrate Dehydrogenase Inhibitors Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Type
13.6.1 IDH1 Mutant Medullary Malignant Tumor
13.6.2 IDH2 Mutant Medullary Malignant Tumor
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Applications
13.10.1 DH Inhibitor
13.10.2 FLT3 Inhibitor
13.10.3 Hedgehog Pathway Inhibitor
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Isocitrate Dehydrogenase Inhibitors Market: Competitive Dashboard
14.2 Global Isocitrate Dehydrogenase Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AGIOS
14.3.2 Aslan Pharmaceuticals
14.3.3 Bayer
14.3.4 Beigene
14.3.5 Bristol-Myers Squibb
14.3.6 Celgene
14.3.7 Daiichi Sankyo
14.3.8 Philogen S.p.A.
14.3.9 Tesaro
14.3.10 Tragara/Adastra
14.3.11 Tocagen
